Case-control study links VEGFA rs833061 variants with bladder cancer and serum YKL-40

A hospital-based case-control study reported that the VEGFA rs833061 promoter polymorphism was associated with bladder cancer susceptibility and circulating YKL-40 concentrations after adjustment for age, sex, and smoking status. The findings, summarized in the article abstract, provide preliminary evidence of a genotype–phenotype relationship but do not establish causation.

The study included 120 patients with bladder cancer and 120 healthy controls matched by age and sex. Investigators genotyped the rs833061 variant using ARMS-PCR and confirmed the genotypes by Sanger sequencing. Serum YKL-40 concentrations were measured with ELISA.

Multivariable binary logistic regression showed that the CT and TT genotypes remained independently associated with increased bladder cancer susceptibility after adjustment for age, sex, and smoking status. Patients had significantly higher serum YKL-40 concentrations than controls, and those concentrations increased progressively with tumor stage. TT genotype carriers had the highest serum YKL-40 levels.

These observations connect a measured genetic variant with two related clinical features in the study population: bladder cancer status and circulating YKL-40. The source available for this report is the article abstract rather than a full assessment of the complete study. The authors characterized the genotype–phenotype relationship as preliminary and stated that the results require validation in larger multicentre cohorts.

Subject of Research: Association of VEGFA rs833061 polymorphism with bladder cancer susceptibility and serum YKL-40 concentrations in a case-control study

Article Title: Integrated analysis of VEGFA rs833061 (− 460T > C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype–phenotype association

Article References: Kaushik, R., Pawar, D., Sharma, A., Siwach, K., Rohilla, G., Narwal, S., Khatri, N., Arora, A., & Vashist, M. (2026). Integrated analysis of VEGFA rs833061 (− 460T > C) promoter polymorphism and serum YKL-40 levels in bladder cancer: evidence of a genotype–phenotype association. Molecular Biology Reports, 53(1), Article 1585. https://doi.org/10.1007/s11033-026-12776-w

Image Credits: AI Generated

DOI: 10.1007/s11033-026-12776-w

Keywords: bladder cancer, VEGFA, rs833061, YKL-40, genetic polymorphism, case-control study, serum biomarker, genotype-phenotype association, Integrated, analysis, promoter, polymorphism